Ovid Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Ovid Therapeutics Inc. (OVID) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $3.03 per share as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $3.03.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $3.13.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $3.49.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $3.56.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $3.03 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.13 10-Q · filed 2026-05-12 |
| 2025-12-31 | $3.49 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.56 10-Q · filed 2025-11-12 |
| 2025-06-30 | $3.83 10-Q · filed 2025-08-13 |
| 2025-03-31 | $4.02 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.07 10-K · filed 2026-03-18 |
| 2024-09-30 | $4.03 10-Q · filed 2024-11-12 |
| 2024-06-30 | $4.06 10-Q · filed 2024-08-13 |
| 2024-03-31 | $4.15 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.47 10-K · filed 2026-03-18 |
| 2023-09-30 | $4.54 10-Q · filed 2023-11-03 |
| 2023-06-30 | $4.64 10-Q · filed 2023-08-04 |
| 2023-03-31 | $4.75 10-Q · filed 2023-05-05 |
| 2022-12-31 | $5.05 10-K · filed 2025-03-11 |
| 2022-09-30 | $5.30 10-Q · filed 2022-11-08 |
| 2022-06-30 | $5.44 10-Q · filed 2022-08-09 |
| 2022-03-31 | $5.83 10-Q · filed 2022-05-10 |
| 2021-12-31 | $5.98 10-K · filed 2024-03-08 |
| 2021-09-30 | $6.26 10-Q · filed 2021-11-10 |
| 2021-06-30 | $6.31 10-Q · filed 2021-08-16 |
| 2021-03-31 | $6.35 10-Q · filed 2021-05-13 |
| 2020-12-31 | $6.45 10-K · filed 2023-03-13 |
| 2020-09-30 | $7.45 10-Q · filed 2020-11-13 |
| 2020-06-30 | $7.54 10-Q · filed 2020-08-10 |
| 2020-03-31 | $7.60 10-Q · filed 2020-05-07 |
| 2019-12-31 | $7.93 10-K · filed 2022-03-15 |
| 2019-09-30 | $7.92 10-Q · filed 2019-11-08 |
| 2019-06-30 | $7.99 10-Q · filed 2019-08-07 |
| 2019-03-31 | $7.99 10-Q · filed 2019-05-07 |
| 2018-12-31 | $7.88 10-K · filed 2021-03-15 |
| 2018-09-30 | $7.88 10-Q · filed 2018-11-08 |
| 2018-06-30 | $7.86 10-Q · filed 2018-08-09 |
| 2018-03-31 | $7.78 10-Q · filed 2018-05-08 |
| 2017-12-31 | $7.65 10-K · filed 2020-03-11 |
| 2016-12-31 | $7.71 10-K · filed 2019-03-07 |
| 2015-12-31 | $0.22 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |